mTOR inhibitors Tank in Three Advanced Kidney Cancer Trials The Oncology Report VIENNA – The mammalian target of rapamycin inhibitors temsirolimus and everolimus have racked up a trio of negative trials in advanced renal cell carcinoma. The phase IIIb INTORACT and phase II RECORD-2 trials show that combinations of bevacizumab ... |
